chartexchange

Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies

Pharmaceutical Technology | Nov 19, 2026 6:41 AM EST

Pfizer is securing ex-China rights to three in vivo CAR-T programmes that are at the pre-IND stage.

Read original article